Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2024 > Vol 5, №11 (2024) > The prognostic value of increasing of high-sensitivity C-reactive protein in chronic heart failure with a preserved ejection fraction. A clinical case

The prognostic value of increasing of high-sensitivity C-reactive protein in chronic heart failure with a preserved ejection fraction. A clinical case

Yuliia S. Belozerskikh , Aleksey I. Kochetkov , Irina F. Krotkova , Irina I. Sinitsina , Olga D. Ostroumova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

We present a clinical case of a 70-year-old man with a long history of chronic heart failure with preserved ejection fraction (HFpEF), treated for decompensated HFpEF, who developed a fatal ischemic stroke during the first year from the initial hospitalization. The reason for the patient's initial hospitalization in the intensive care unit was decompensation of HFpEF; on the first day, the level of high-sensitivity C-reactive protein in the blood serum was 7.53 mg/l. During the hospitalization, conservative drug therapy was carried out, the patient was discharged in satisfactory condition, and treatment recommendations were given in accordance with current clinical guidelines. 360 days after discharge, the patient was readmitted to the hospital in the intensive care unit due to acute ischemic stroke in the left middle cerebral artery, cerebral edema, and dislocation syndrome. A day later the patient's death was recorded. Using this clinical case as an example, the article discusses the issue of high-sensitivity C-reactive protein levels as a predictor of an increased risk of adverse outcomes in patients with HFpEF.
Keywords: chronic heart failure, ischemic stroke, prognosis, high-sensitivity C-reactive protein, clinical case.

About the Author

Yuliia S. Belozerskikh 1 , Aleksey I. Kochetkov 2 , Irina F. Krotkova 2 , Irina I. Sinitsina 2 , Olga D. Ostroumova 3

1 Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Sklifosovsky Research Institute For Emergency Medicine, Moscow, Russia

2 Russian Medical Academy of Continuous Professional Education, Moscow, Russia

3 Russian Medical Academy of Continuous Professional Education, Moscow, Russia; Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

References

1. Sun F, Yuan L, Wang Z et al. Cardiac sympathetic overdrive, M2 macrophage activation and fibroblast heterogeneity are associated with cardiac remodeling in a chronic pressure overload rat model of HFpEF. Front Pharmacol 2024;27(15):1364758.
2. Desai AS, Lam CSP, McMurray JJV et al. How to Manage Heart Failure With Preserved Ejection Fraction: Practical Guidance for Clinicians. JACC Heart Fail 2023;11(6):619-36.
3. Ukrust P, Yndestad A, Damås JK et al. Inflammation and chronic heart failure-potential therapeutic role of intravenous immunoglobulin. Autoimmun Rev 2004;3(3):221-7.
4. Morelli S, Di Girolamo F, Angelino A et al. Anaemia as an inflammation-mediated condition during chronic heart failure. Possible role of fibrinogen. Acta Cardiol 2008;63(5):565-70.
5. Kalogeropoulos AP, Tang WH, Hsu A et al. High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial.
J Card Fail 2014;20(5):319-26.
6. Al Aseri ZA, Habib SS, Marzouk A. Predictive value of high sensitivity C-reactive protein on progression to heart failure occurring after the first myocardial infarction. Vasc Health Risk Manag 2019;(15):221-7.

For citation:Belozerskikh Yu.S., Kochetkov A.I., Krotkova I.F., Sinitsina I.I., Ostroumova O.D. The prognostic value of increasing of high-sensitivity C-reactive protein in chronic heart failure with a preserved ejection fraction. A clinical case. Clinical review for general practice. 2024; 5 (11): 6–10 (In Russ.). DOI: 10.47407/kr2024.5.11.00510


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru